A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(4 sites)

China

Peking union medical college hospital, Beijing, Beijing Municipality

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei

West China Hospital Sichuan University, Chengdu, Sichuan

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality